Monica-Daniela Padurariu-Covit

Dr. Monica-Daniela Padurariu-Covit

Department of Hematology, Sf Apostol Andrei Emercency County Hospital, 800366 Galati, Romania
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2025 in Viruses
Verified
Journal Article
Open access
PDF file
Monica-Daniela Padurariu-CovitMonica-Daniela Padurariu-Covit
Monica-Daniela Padurariu-Covit
GCGeorgescu Costinela
Georgescu Costinela
Mihaela AndreescuMihaela Andreescu
Mihaela Andreescu
ICIulia Chiscop
Iulia Chiscop
CPCatalin Plesea-Condratovici
Catalin Plesea-Condratovici
MAManuela Arbune
Manuela Arbune
Antiretroviral therapy (ART) effectively suppresses HIV replication but fails to eradicate latent reservoirs, leading to viral rebound after interruption. Chimeric antigen receptor (CAR) T-cell therapy offers a potential strategy to achieve durable remission. A systematic PubMed search (July 2020–June 2025) identified 253 studies on CAR-T therapy in HIV; 74 met inclusion criteria and were qualitatively analyzed. Preclinical data showed that CAR-T cells can recognize and eliminate infected cells, reach viral reservoirs, and persist long term, particularly when derived from hematopoietic stem cells. Dual-target and combination approaches with checkpoint inhibitors or latency-reversing agents enhanced antiviral efficacy. Early clinical studies confirmed safety and modest reservoir reduction. CAR-T cell therapy represents a promising step toward a functional HIV cure. Further optimization of design, integration with gene-editing technologies, and standardized clinical evaluation are required to confirm durable efficacy and safety.

17 November 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MAManuela Arbune
Manuela Arbune
Monica-Daniela Padurariu-CovitMonica-Daniela Padurariu-Covit
Monica-Daniela Padurariu-Covit
LRLaura –Florentina Rebegea
Laura –Florentina Rebegea
GLGabriela Lupasteanu
Gabriela Lupasteanu
AAAnca-Adriana Arbune
Anca-Adriana Arbune
Alin Laurentiu TATUAlin Laurentiu TATU
Alin Laurentiu TATU
Kaposi’s sarcoma (KS) was peculiarly described in the first notified cases of the acquired immunodeficiency syndrome as an opportunistic condition. However, the medical progress and the development of active antiretroviral therapy allowed the control of the HIV/AIDS epidemic, although the features of KS have changed throughout the past decades. The purpose of our study is to assess the epidemiological and clinical features of AIDS related KS in Romanian patients. A retrospective follow-up study was achieved in a single infectious diseases’ clinic from Galati—Romania, between 2001 and 2021. Referring to 290 new HIV diagnosed cases from our clinic retained in care, the prevalence of KS was 3.4%. The main characteristics of patients with KS are a median age of 33, a predominance of males, prevalent severe systemic forms of diseases, frequent association of past or concomitant tuberculosis, and context of immune reconstruction syndrome. The mortality rate was 70%. KS has occurred in patients with delayed HIV diagnoses and inadequate adherence to therapy. Early recognition of both infections, the close monitoring of latent or symptomatic tuberculosis, improving the antiretroviral adherence and raising the access to oncologic procedures in Romanian HIV patients could improve their prognosis related to KS.

29 September 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DDDalma Deak
Dalma Deak
SISabina Iluta
Sabina Iluta
Sergiu PascaSergiu Pasca
Sergiu Pasca
CJCiprian Jitaru
Ciprian Jitaru
ARAndrei Roman
Andrei Roman
CTCiprian Tomuleasa
Ciprian Tomuleasa
Introduction. Primary central nervous system lymphoma is an uncommon form of extranodal non-Hodgkin’s lymphoma, with increasing incidence, a relatively aggressive course and a poor 5-year survival. Because of its localization, the therapeutic compounds used in this disease must be able to pass through the blood-brain barrier. Chemotherapy regimens based on high-dose methotrexate are currently the standard of care for all patients who can tolerate such drugs. Autologous stem cell transplantation is indicated for malignant lymphomas in the relapsed/refractory setting. Methods. Three patients, with a median age of 60 years, range 53–64, were diagnosed with primary CNS lymphoma, and treated with ibrutinib monotherapy in the Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj-Napoca, Romania, between September 2018 and November 2020 All the patients were relapsed–refractory following high-dose methotrexate chemotherapy. We present our experience using ibrutinib monotherapy-based treatment as a bridge-to-transplant option on a single-center case series and a review of the literature in this field. Results. Two of the patients were given ibrutinib as a second line therapy, both achieving complete remission and being eligible for an autologous stem cell transplantation. The third patient achieved a short remission using six cycles of systemic chemotherapy, but was started on ibrutinib monotherapy, with limited results. Conclusion. Our data is limited, and these results should be confirmed by multicentric clinical trials and should be regarded as a single-center case series, with all its limitations. Still, it brings forward a new therapeutic option for this rare subtype of malignant lymphomas, which if left untreated has a dismal prognosis.

Verified
Journal Article
Open access
PDF file
MAManuela Arbune
Manuela Arbune
Monica-Daniela Padurariu-CovitMonica-Daniela Padurariu-Covit
Monica-Daniela Padurariu-Covit
CTCarmen Tiutiuca
Carmen Tiutiuca
RMRaul Mihailov
Raul Mihailov
Elena NiculetElena Niculet
Elena Niculet
Alin Laurentiu TATUAlin Laurentiu TATU
Alin Laurentiu TATU
Kaposi’s sarcoma is an AIDS-defining illness and remains the most frequent tumor arising in HIV-infected patients with multifactorial etiology. We present a case of a 30-year-old Caucasian male with an 18-year history of HIV infection. The patient was presented with a one-week history of fever, non-productive cough, and skin lesions. There was an associated weakness and weight loss in a duration of 6 months. Clinical examination showed fever, generalized lymphadenopathy, lower limb edema, ascites, and violaceous cutaneous eruption comprising patches, plaques, and nodules. He also had a red nodule on the left conjunctiva, as well as on his oral mucosa. His CD4+ count was below 10/mm3 and ARN-HIV viral load was above 100,000 c/mL, in relation to the antiretroviral failure after five drug regimens. The role of co-infections in oncogenesis and the course of Kaposi’s sarcoma were considered in recent studies. Delayed diagnosis of Kaposi’s sarcoma in the present case resulted in a negative impact for this patient during the COVID-19 pandemic.

12 March 2025 in Viruses
Verified
Journal Article
Open access
PDF file
Monica-Daniela Padurariu-CovitMonica-Daniela Padurariu-Covit
Monica-Daniela Padurariu-Covit
Mihaela AndreescuMihaela Andreescu
Mihaela Andreescu
Elena NiculetElena Niculet
Elena Niculet
CPCatalin Plesea-Condratovici
Catalin Plesea-Condratovici
MAManuela Arbune
Manuela Arbune
The COVID-19 pandemic delayed the consultation of many patients with specialists. We present the case of a 57-year-old patient with HIV infection, COVID-19 pneumonia, and Hodgkin lymphoma. Discordant immunohistochemistry results from biopsy samples delayed the hematological diagnosis and initiation of oncological therapy. The late diagnosis of HIV infection at the stage of severe immunosuppression, along with advanced Hodgkin lymphoma and COVID-19 co-infection, represents a complex pathogenic triad that is challenging to manage. Healthcare-associated COVID-19 infections pose a significant risk during the pandemic for chronic patients requiring frequent hospital visits.

10 December 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
MAManuela Arbune
Manuela Arbune
AIAlina-Viorica Iancu
Alina-Viorica Iancu
Monica-Daniela Padurariu-CovitMonica-Daniela Padurariu-Covit
Monica-Daniela Padurariu-Covit
CPCatalin Plesea-Condratovici
Catalin Plesea-Condratovici
AAAnca-Adriana Arbune
Anca-Adriana Arbune
CPCatalin Plesea-Condratovici
Catalin Plesea-Condratovici
Background: Co-infections with HIV, HBV, and HDV pose significant public health challenges, especially in populations exposed parenterally. Romania hosts a unique pediatric HIV cohort of individuals born 1987–1995 who acquired HIV iatrogenically. This study assessed the prevalence, hepatic impact, and management of HIV–HBV–HDV co-infection in 130 long-term survivors from Galați County. Methods: Patients underwent clinical, laboratory, and FibroScan assessments. HBV and HDV serology and viral loads were measured, and antiretroviral therapy regimens, including tenofovir-based therapies, were reviewed. Entecavir or Bulevirtide was applied when indicated. Results: HBV infection was present in 57.7% of cohort patients versus 20% in non-cohort PLWH, and HDV co-infection in 7.7% of cohort patients. Hepatic fibrosis increased from HBV-uninfected to HBV/HDV co-infected individuals. HIV impairs viral clearance and exacerbates liver injury via immune dysregulation and chronic inflammation. Despite TDF-based ART, replicative HBV was detected in eight patients, managed with Entecavir. Bulevirtide therapy for HDV was initiated in eligible patients, with minor adverse events. Conclusions: Pediatric HIV cohort survivors show high rates of HBV and HDV co-infection and progressive hepatic fibrosis. Optimized antiviral therapy and adherence support are essential to control viral replication and reduce liver-related complications.